MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: *Investment Round
Venture Capital: Series A
Triumvira Immunologics
Attachments
Triumvira Immunologics - Triumvira Immunologics | Car-T, TCR, TAC Therapies and Immunotherapy
Parents
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology
*Industry: Texas
Venture Capital: Series A
Children
2020: Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics
Austin, Texas
Clinical stage immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies
Founded 2015
Jumps
Bayer AG (ADR) (BAYRY)